Speaker Profile
M.D., Ph.D., Assistant Professor, Director Solid Tumor Cell Therapy, Stanford U.
Biography
Dr. Betof Warner is a board certified medical oncologist specializing inadvanced melanoma treatment. She serves as the Director of Melanoma MedicalOncology, Director of Solid Tumor Cellular Therapy, and coDirector of thePigmented Lesion and Melanoma Program. A pioneer in tumor infiltratinglymphocyte (TIL) therapy, she leads the Melanoma Cutaneous OncologyClinical Research Group, focusing on tumor response to immunotherapy.Recognized for her expertise in central nervous system metastases and novelcellular therapies, she's collaborated globally and received accolades fromASCO, NIH, and the Melanoma Research Foundation. Dr. Betof Warner is anactive member of several professional organizations, including the AmericanAssociation for Cancer Research and the Society for Immunotherapy ofCancer.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Priti Hegde, Kite Pharma
PMWC Award Ceremony
• Michel Sadelain, Columbia University
• Arie S. Belldegrun, Allogene Therapeutics
Keynote: Engineering the Future: Innovations in CAR-T Therapy Design
• Michel Sadelain, Columbia University
CAR-T Cell Therapies: Strategies in Mitigating Challenges in Solid Tumor Delivery
• Chair: David Barrett, Kite Pharma
• Carl June, University of Pennsylvania
• Michel Sadelain, Columbia University
Tumor-Infiltrating Lymphocytes (TILs): Advances and Challenges in Solid Tumors
• Chair: Allison Betof Warner, Stanford University
• George Coukos, Ludwig Institute for Cancer Research
• Max Julve, Royal Marsden
• Stephanie Goff, NIH/NCI
Allogeneic & In Vivo Cell Therapies: Manufacturing & Clinical Progress
• Chair: Arie S. Belldegrun, Allogene Therapeutics
• David Chang, Allogene Therapeutics
• Adrian Bot, Capstan Therapeutics
• Aliya Omer, AstraZeneca
• Priti Hegde, Kite Pharma
Designing Automated Platforms for Scalable Cell Therapy Manufacturing
• Fabian Gerlinghaus, Cellares
TCR-Based Cell Therapies: New Targets and Clinical Advances
• Chair: Diwakar Davar, UPMC
• Lauren Harshman, Clasp Therapeutics
• Cassian Yee, MD Anderson Cancer Center
Gene Editing & Synthetic Biology for Therapy
• Chair: Matthew Porteus, Stanford University
• Rachel Haurwitz, Caribou Biosciences
• Kole T. Roybal, Parker Institute
• Ken Drazan, ArsenalBio
In-Vivo Myeloid Programming: Engineering the Innate Immune System for Solid Tumor Therapy
• Daniel Getts, Create Medicines
Synthetic Circuits for Smarter Cell Therapies: Enhancing NK Precision and Persistence
• Gudrun Stengel, Alida Biosciences
